The University of Texas MD Anderson Cancer Center today announced a $10 million gift to the James P. Allison Institute from the Andrew Sabin Family Foundation and Andrew “Andy” Sabin, a senior member of the MD Anderson Cancer Center Board of Visitors (BOV). The gift is the philanthropist’s second multimillion-dollar commitment to MD Anderson in less than 10 years.
MD Anderson and Exscientia today announced a strategic collaboration to align the drug development expertise of MD Anderson with the patient-centric AI capabilities of Exscientia to advance new targeted cancer therapies.
Eyal Gottlieb, Ph.D., has been named MD Anderson’s vice president for Research. Gottlieb, an accomplished scientist and leader, will join the institution in January to uphold and expand the institution’s research excellence.
This special edition features upcoming presentations by MD Anderson researchers at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, including immunotherapy advances in human papillomavirus (HPV)-positive head and neck cancers, microbiome signatures linked with specialized immune-cell clusters, and promising early activity from novel immunotherapy drugs in advanced melanoma and colorectal cancer.
Thousands are expected at MD Anderson’s Boot Walk to End Cancer® on Saturday, Nov. 5, as The University of Texas MD Anderson Cancer Center prepares for the in-person return of the seventh annual event in the Texas Medical Center.
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were presented today at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.
Using a novel response-adapted ultra-low dose radiation therapy strategy, MD Anderson researchers observed a 90% complete response rate in patients with orbital indolent B-cell lymphoma. The results were presented today at the 2022 ASTRO Annual Meeting.
MD Anderson’s James P. Allison institute today announced the establishment of its internal advisory council to provide scientific input and to align the work of the institute with the broader MD Anderson research enterprise.
MD Anderson and ARTIDIS today announced a strategic alliance to investigate ARTIDIS nanotechnology platform as a treatment-optimization tool for patients with solid tumors.
MD Anderson and Radiopharm Theranostics today announced the launch of Radiopharm Ventures, LLC, a joint venture created to develop novel radiopharmaceutical therapeutic products for cancer.
MD Anderson researchers used extensive single-cell analysis to create a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, revealing new roles for these immune cells in cancer development and immunotherapy responses.
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial were presented today at the European Society for Medical Oncology (ESMO) Congress 2022.
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology (ESMO) Congress 2022.
MD Anderson and Virogin Biotech today announced a strategic collaboration to accelerate the development of oncolytic virus therapies for advanced cancers.
MD Anderson and Erasca announced a strategic research and development collaboration to evaluate multiple agents from Erasca’s pipeline targeting the RAS/MAPK pathway in cancer.
The targeted therapy pralsetinib was well-tolerated and demonstrated high response rates in patients with RET gene fusions regardless of tumor type, according to results from the Phase I/II ARROW trial.
MD Anderson and Empyrean announced an exclusive license and joint development agreement to advance new technologies and products in radiation oncology.
MD Anderson and TransCode announced a strategic alliance to advance TransCode’s pipeline of RNA-targeted therapeutic and diagnostic candidates for oncology.
MD Anderson will host the virtual Cancer Neuroscience Symposium Sept. 22-23, 2022, in collaboration with the journal Advanced Biology. The symposium is free to attend and gathers leading experts in the field to discuss a variety of topics on the relationship between cancer biology and neuroscience. Registration includes the opportunity to participate in an abstract competition and to view sessions following the event.
Clinical advances include treating hematologic cancers with effective targeted therapies, circulating tumor DNA as a biomarker for recurrence with colorectal liver metastases, and using magnetic resonance imaging (MRI) to guide surgical decisions for patients with lateral pelvic lymph node metastases in rectal cancer. Laboratory findings offer new understanding of the pancreatic cancer immune microenvironment, melanoma cell states, TP53 mutation status in acute myeloid leukemia (AML), and potential targets for metastatic prostate cancer and GNAS-mutant colorectal cancer.
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report’s 2022-23 “Best Hospitals” rankings.
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased survival relative to historical data and compared favorably to FOLFIRINOX plus hypofractionated radiotherapy, according to research from The University of Texas MD Anderson Cancer Center published today in JAMA Oncology.
The University of Texas MD Anderson Cancer Center today announced Kimberly Hoggatt Krumwiede, Ph.D., as dean of MD Anderson’s School of Health Professions (SHP), effective Aug. 1.
MD Anderson and Turning Point Therapeutics announced a strategic research and development alliance to evaluate Turning Points investigational targeted therapies against ROS1, NTRK, MET and other cancer drivers.
Researchers have developed a mathematical tool to estimate tumor-specific RNA levels from tumor samples with mixed cell types. Using this technique on thousands of samples found that higher mRNA levels are correlated with shorter survival.
A new genetic study discovered that not all breast cancers that develop after DCIS arise from the original DCIS lesion. Roughly 1 in 5 are new cancers, genetically unrelated to the original DCIS.
Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant.
Combination chemoimmunotherapy with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The study results also were published today in the New England Journal of Medicine.
MD Anderson and Resilience today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, which unites the strengths of both parties to accelerate the development and manufacturing of cell therapies for patients with cancer.
This special edition features upcoming oral presentations by MD Anderson researchers at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting focused on quality improvement, health services research, new treatments for skin cancers, and symptoms and survivorship advances. More information on ASCO content from MD Anderson can be found at MDAnderson.org/ASCO.
This special edition of MD Anderson’s Research Highlights features presentations at the Society for Immunotherapy of Caner 36th Annual Meeting.
In a new single-arm study, researchers at The University of Texas MD Anderson Cancer Center reported that radiation therapy as monotherapy is a safe and effective noninvasive treatment for oligometastatic renal cell carcinoma (RCC). The findings were published today in The Lancet Oncology
MD Anderson and Siemens Healthineers have announced the collaborative development of an education program focused on enabling the implementation of consistent, high-quality MRI in radiation oncology.
A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. This is the first demonstration of a survival advantage with a front-line CDK4/6 inhibitor in postmenopausal patients with
HR+/HER 2- advanced breast cancer.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and clinical cancer research from MD Anderson experts. This special edition features oral presentations by MD Anderson researchers at the virtual European Society for Medical Oncology (ESMO) Congress 2021 on novel therapeutic approaches, including cell therapy for solid tumors, antibody drug conjugates targeting TROP2 and neoadjuvant pembrolizumab for advanced solid tumors with mismatch repair deficiencies.
A new study in Science finds that pancreatic cells display an adaptive response to repeated inflammation that initially protects against tissue damage but can promote tumor formation in the presence of mutant KRAS.
MD Anderson to honor the life of trailblazing oncologist Emil J Freireich, M.D., in a virtual tribute event on Sept. 23
A new study from researchers at The University of Texas MD Anderson Cancer Center showed that stereotactic ablative radiotherapy (SABR) was as effective as surgery at providing long-term benefits to patients with operable early-stage non-small cell lung cancer (NSCLC) and generated minimal side effects. The study is the first of its kind to compare long-term results of SABR against surgical treatment in patients with operable early-stage NSCLC.
MD Anderson and SNIPR BIOME have announced a strategic collaboration to advance next-generation CRISPR-based microbiome therapies to reduce immune-related side effects in patients treated with immune checkpoint inhibitors.
The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum’s CaspaCIDe® (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch.
Omer Sultan joins MD Anderson as new Chief Financial Officer
A study led by researchers from The University of Texas MD Anderson Cancer Center found a significant association between cholesterol-lowering drugs commonly known as statins and survival rates of triple-negative breast cancer patients. Since statins are low in cost, easy to access and produce minimal side effects, this could have an important impact on outcomes for this aggressive disease.
MD Anderson hosts the Leading Edge of Cancer Research Symposium on November 4-5, 2021, featuring presentations from distinguished cancer researchers and a virtual poster session, open to all.
MD Anderson and Blueprint Medicines announced a three-year strategic collaboration to accelerate the development of BLU-222, an investigational targeted therapy against CDK2.
A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.
MD Anderson and Hummingbird Bioscience announced a multi-year strategic research collaboration to investigate HMBD-002, Hummingbird’s VISTA antagonist antibody, as a novel immunotherapy for cancer.
Preclinical research finds that glioblastoma stem cells can be targeted by NK cells, but they are able to evade immune attack by releasing TFG-β. Deleting the TFG-β receptor in NK cells renders them resistant to this and restores their anti-tumor activity.
A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest follow-up data on patients treated with this drug regimen.
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer.
MD Anderson researchers have discovered a new role for the metabolic enzyme, MCAD, in glioblastoma. The enzyme prevents toxic fatty acid accumulation, in addition to its normal role in energy production, and targeting MCAD led to irreversible damage and cell death specifically in cancer cells.